It combines antipyrine, an NSAID, and benzocaine, a local anaesthetic in order to treat ear pain, alongside hydroxyquinoline sulfate, an antiseptic and preservative.
Its trade names include Auralgan, Aurodex, Auroto,[1] among others, and is abbreviated as A/B otic drops.
In 2008, Auralgan was reformulated to include acetic acid and U-polycosanol 410, in addition to antipyrine and benzocaine.
Due to this reformulation, pharmacies could no longer substitute the generic antipyrine/benzocaine drops for a prescription written as "Auralgan".
The FDA has not evaluated this drug for safety, effectiveness or quality and has concerns about inappropriate dosing and risk of contamination during the manufacturing process.